The Global Male Infertility Market size accounted for US$ 3,834 Mn in 2021 and is estimated to reach US$ 5,885 Mn by 2030, with a significant CAGR of 5.0% from 2022 to 2030.
Male infertility is a significant problem in today's society. Infertility has historically been regarded to be a female issue. However, males are responsible for infertility almost half of the time. The issue often stems from the process of either making or moving sperm, which can be caused by a variety of factors such as varicocele, genetic abnormalities, hormonal disorders, an undescended testicle, and the use of anabolic steroids or anti-seizure medications. Another important issue is getting the sperm to where it has to go. Men with this type of infertility have normal sperm counts in their testicles, but their sperm count in their sperm is either abnormal, very low, or non-existent. Retrograde ejaculation, blockage, anti-sperm antibodies, and the absence of the main sperm pipeline known as the vas deferens induce this form of infertility. According to estimates, idiopathic infertility affects more than 25% of infertile males. That means they have low or aberrant sperm counts for no apparent cause. Male fertility market revenue is been generating progressively due to the advancement in fertility treatment.
Market Growth Drivers:
- Changing lifestyle
- High adoption of assisted reproductive technology (ART)
- Increasing awareness among the people
Market Restraints:
- High cost of treatment
- Repeated treatment failures
Market Opportunities:
- Advancement in infertility treatments
- Growing healthcare infrastructure
Report Coverage
Market |
Male Infertility Market |
Market Size 2021 |
US$ 3,834 Mn |
Market Forecast 2030 |
US$ 5,885 Mn |
CAGR |
5.0% During 2022 - 2030 |
Analysis Period |
2018 - 2030 |
Base Year |
2021 |
Forecast Data |
2022 - 2030 |
Segments Covered |
By Test, By Treatment, By End-User, And By Geography
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled |
Andrology Solutions, Halotech DNA SL, AytuBioScience, Inc., Bayer Healthcare, EMD Sereno, Inc., Cadila Healthcare Ltd., SCSA Diagnostics, Inc., and Intas Pharmaceuticals Ltd. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Customization Scope |
10 hrs of free customization and expert consultation
|
Male Infertility Market Dynamics
Male infertility is typically caused by spermatogenesis issues. This can be related to poor testicular function, hormonal issues, or blockages in the male urogenital system. Male fertility can arise for a variety of reasons, including both reversible and irreversible diseases. Changing lifestyle is one of the important trends in male infertility market that is supporting the industry growth. Alcohol and tobacco usage, as well as participation in high-intensity sports or activities that may expose testicles to high temperatures(like saunas or occupational exposures), can all contribute to infertility. In addition to that, other factors that are responsible for male infertility are overweight or obesity, age more than 40, exposure to radiation, azoospermia, oligospermia, malformed sperm, cancer treatments, etc.
Assisted reproductive techniques (ARTs) are one of the treatment techniques that are on a boom due to the rising cases of male infertility. ARTs are high-tech ways for joining sperm and egg when intercourse fails. Intrauterine insemination (IUI), in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and sperm retrieval for ART are some of the most used assisted reproductive technologies.
Growing awareness among male infertility treatments are expected to boost the demand throughout the forecast period 2022 – 2030. Regions such as North America and Europe have a larger portion of the male infertility market because of the increased awareness in their countries. Male infertility cases are seldom reported in underdeveloped countries due to social stigma and cultural fears, despite the fact that the number of instances is considerable in these countries. Furthermore, continuous R&D efforts are made to have a deeper knowledge of the idiopathic realm of infertility. As a result, corporations are investing in the development of equipment for determining the fundamental cause and providing focused treatment.
Male Infertility Market Segmentation
The global male infertility market is segmented based on test, treatment, end-user, and geography.
Market by Test
· Oxidative Stress Analysis
· DNA Fragmentation Technique
· Microscopic Examination
· Sperm Agglutination
· Computer Assisted Semen Analysis
· Sperm Penetration Assay
· Others
Based on our analysis, the DNA fragmentation technique segment achieved a considerable amount of male infertility market share in 2021. Sperm DNA fragmentation tests evaluate the quality of the DNA package that contains the offspring's critical genetic information. As a result, the tests are unique and more significant than traditional sperm parameters. Sperm chromatin structure assay (SCSA), single-cell gel electrophoresis (Comet) assay, terminal transferase dUTP nick end labeling (TUNEL) assay and sperm chromatin dispersion (SCD or Halo) test are the most often utilized tests. These tests evaluate different aspects of DNA damage and have varying sensitivity.
Market by Treatment
- Medication
- Assisted Reproductive Technology and Varicocele Surgery
Out of these, the assisted reproductive technology and varicocele surgery segment held the largest male infertility market share in 2021 as these procedures are mostly preferred for men. In addition to that, male infertility is treated with ARTs due to main causes such as sperm autoantibodies, epididymal malfunction, viral orchitis, chemotherapy, heat, accessory gland infection, trauma, and other idiopathic variables. On the other hand, varicoceles are enlarged scrotal veins. They are discovered in 16 out of every 100 men. They are more prevalent in infertile guys (40 out of 100). Varicoceles can be corrected with a modest outpatient procedure known as varicocelectomy. Repairing enlarged veins improves sperm mobility, quantity, and shape.
Market by End-User
- Hospitals and Clinics
- Fertility Centers
- Research Institutes
- Others
Among them, the fertility centers segment held for the maximum market share during the forecasted timeframe from 2022 to 2030. Fertility centers have dedicated healthcare professionals that treat males with persice medication. Furthermore, this segment is also anticipated to attian the fastest growth rate throughout the forecast period. Growing number of fertility centers across the world is also expected to support the industry growth.
Male Infertility Market Regional Overview
North America
· U.S.
· Canada
Europe
· U.K.
· Germany
· France
· Spain
· Rest of Europe
Latin America
· Mexico
· Brazil
· Rest of Latin America
Asia-Pacific
· India
· Japan
· China
· Australia
· South Korea
· Rest of Asia-Pacific
The Middle East & Africa (MEA)
· Gulf Cooperation Council (GCC)
· South Africa
· Rest of the Middle East & Africa
Better Coverage for Diagnosis and Treatment Boosts the Europe Male Infertility Market Revenue
North America, Latin America, Asia-Pacific, Europe, and the Middle East and Africa are the regional segments (MEA). Europe will account for a substantial portion of revenue in 2021 because of the availability of advanced fertility facilities, a high level of knowledge, and higher acceptance of more expensive therapy. North America generated the second largest market share due to an increase in male infertility caused by lifestyle variables such as obesity and diet, as well as technology breakthroughs that are meeting the need for treatment. Meanwhile, the Asia-Pacific area is predicted to grow at the quickest rate in the next years. The expanding elderly population, combined with an increase in lifestyle-related disorders, has led in an increase in male infertility.
Competitive Landscape
Some of the top vendors offered in the professional report include Andrology solutions, Halotech DNA SL, AytuBioScience, Inc., Bayer Healthcare, EMD Sereno, Inc., Cadila Healthcare Ltd., SCSA Diagnostics, Inc., and Intas Pharmaceuticals Ltd.
CHAPTER 1. Industry Overview of Male Infertility Market
1.1. Definition and Scope
1.1.1. Definition of Male Infertility
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Male Infertility Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Male Infertility Market By Test
1.2.3. Male Infertility Market By Treatment
1.2.4. Male Infertility Market By End-User
1.2.5. Male Infertility Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Male Infertility Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Male Infertility Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Male Infertility Market By Test
4.1. Introduction
4.2. Male InfertilityRevenueBy Test
4.2.1. Male Infertility Revenue (US$ Mn) and Forecast, By Test, 2018-2030
4.2.2. Oxidative Stress Analysis
4.2.2.1. Oxidative Stress Analysis Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
4.2.3. DNA Fragmentation Technique
4.2.3.1. DNA Fragmentation Technique Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
4.2.4. Microscopic Examination
4.2.4.1. Microscopic Examination Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
4.2.5. Sperm Agglutination
4.2.5.1. Sperm Agglutination Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
4.2.6. Computer Assisted Semen Analysis
4.2.6.1. Computer Assisted Semen Analysis Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
4.2.7. Sperm Penetration Assay
4.2.7.1. Sperm Penetration Assay Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
4.2.8. Others
4.2.8.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
CHAPTER 5. Male Infertility Market By Treatment
5.1. Introduction
5.2. Male Infertility Revenue (US$ Mn) By Treatment
5.2.1. Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
5.2.2. Assisted Reproductive Technology and Varicocele Surgery
5.2.2.1. Assisted Reproductive Technology and Varicocele SurgeryMarket Revenue (US$ Mn) and Growth Rate (%), 2018-2030
5.2.3. Medication
5.2.3.1. Medication Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
CHAPTER 6. Male Infertility Market By End-User
6.1. Introduction
6.2. Male Infertility Revenue (US$ Mn) By End-User
6.2.1. Male Infertility Revenue (US$ Mn) and Forecast By End-User, 2018-2030
6.2.2. Hospitals & Clinics
6.2.2.1. Hospitals & Clinics Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.3. Fertility Centers
6.2.3.1. Fertility Centers Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.4. Research Institutes
6.2.4.1. Research Institutes Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.5. Others
6.2.5.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
CHAPTER 7. North AmericaMale Infertility Market By Country
7.1. North America Male InfertilityOverview
7.2. U.S.
7.2.1. U.S. Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
7.2.2. U.S. Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
7.2.3. U.S. Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
7.3. Canada
7.3.1. Canada Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
7.3.2. Canada Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
7.3.3. Canada Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
7.4. North America PEST Analysis
CHAPTER 8. Europe Male Infertility Market By Country
8.1. Europe Male InfertilityOverview
8.2. U.K.
8.2.1. U.K.Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
8.2.2. U.K. Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
8.2.3. U.K. Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
8.3. Germany
8.3.1. Germany Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
8.3.2. Germany Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
8.3.3. Germany Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
8.4. France
8.4.1. France Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
8.4.2. France Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
8.4.3. France Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
8.5. Spain
8.5.1. Spain Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
8.5.2. Spain Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
8.5.3. Spain Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
8.6. Rest of Europe
8.6.1. Rest of Europe Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
8.6.2. Rest of Europe Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
8.6.3. Rest of Europe Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Male Infertility Market By Country
9.1. Asia Pacific Male InfertilityOverview
9.2. China
9.2.1. China Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
9.2.2. China Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
9.2.3. China Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
9.3. Japan
9.3.1. Japan Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
9.3.2. Japan Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
9.3.3. Japan Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
9.4. India
9.4.1. India Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
9.4.2. India Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
9.4.3. India Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
9.5. Australia
9.5.1. Australia Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
9.5.2. Australia Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
9.5.3. Australia Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
9.6. South Korea
9.6.1. South Korea Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
9.6.2. South Korea Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
9.6.3. South Korea Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-PacificMale Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
9.7.2. Rest of Asia-Pacific Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
9.7.3. Rest of Asia-Pacific Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Male Infertility Market By Country
10.1. Latin AmericaMale InfertilityOverview
10.2. Brazil
10.2.1. Brazil Male Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
10.2.2. Brazil Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
10.2.3. Brazil Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
10.3. Mexico
10.3.1. MexicoMale Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
10.3.2. Mexico Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
10.3.3. Mexico Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
10.4. Rest of Latin America
10.4.1. Rest of Latin AmericaMale Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
10.4.2. Rest of Latin America Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
10.4.3. Rest of Latin America Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Male Infertility Market By Country
11.1. Middle East & Africa Male InfertilityOverview
11.2. GCC
11.2.1. GCCMale Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
11.2.2. GCC Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
11.2.3. GCC Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
11.3. South Africa
11.3.1. South AfricaMale Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
11.3.2. GCC Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
11.3.3. GCCMale Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & AfricaMale Infertility Revenue (US$ Mn) and Forecast By Test, 2018-2030
11.4.2. Rest of Middle East & Africa Male Infertility Revenue (US$ Mn) and Forecast By Treatment, 2018-2030
11.4.3. Rest of Middle East & Africa Male Infertility Revenue (US$ Mn) and Forecast ByEnd-User, 2018-2030
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Male Infertility Market
12.1. Male Infertility MarketCompany Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition InGlobal Male Infertility Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. Andrology Solutions
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (US$ Mn), 2021
13.1.3.2. Andrology solutions2021 Male InfertilityBusiness Regional Distribution
13.1.4. Product/Service Specification
13.1.5. Recent Developments & Business Strategy
13.1.6. ManufacturingPlant Footprint Analysis
13.2. AytuBioScience, Inc.
13.3. Bayer Healthcare
13.4. Cadila Healthcare Ltd.
13.5. EMD Sereno, Inc.
13.6. Halotech DNA SL
13.7. Intas Pharmaceuticals Ltd.
13.8. SCSA Diagnostics, Inc.